大葉大學圖書館 |

Genome editing in drug discovery[electronic resource] /

紀錄類型:	書目-電子資源 : Monograph/item
杜威分類號:	615.1/9
書名/作者:	Genome editing in drug discovery/ Marcello Maresca, Sumit Deswal.
其他作者:	Maresca, Marcello.
出版者:	Hoboken, NJ : : Wiley,, 2022.
面頁冊數:	1 online resource (x, 342 p.) : : ill. (chiefly col.)
標題:	Drug development.
標題:	Genetic engineering.
ISBN:	9781119671404
ISBN:	111967140X
ISBN:	9781119671398
ISBN:	1119671396
ISBN:	9781119671381
ISBN:	1119671388
書目註:	Includes bibliographical references and index.
摘要、提要註:	"CRISPR-Cas has revolutionized genome editing by allowing researchers to remove, alter, or add sections of the DNA sequence. By performing large scale functional genomics screens with CRISPR-Cas, scientists can identify and validate drug targets at a much faster rate. Genome editing is now part of almost every step in the drug discovery pipeline, from target identification and its validation to mechanistic studies in relevant disease models to therapeutic genome editing and disease diagnosis. Genome Editing in Drug Discovery offers comprehensive coverage of the revolution CRISPR-Cas has brought to genome editing and its impact on drug discovery. Ideal for academics, researchers, and professionals in the pharmaceutical industry; this book helps readers create better disease models, assess the safety and efficacy of drugs, discover new targets, and develop next-generation diagnostics for disease-related genes. This book provides a historical prospective on genome editing, discusses the general approaches used to make disease models, and offers practical suggestions as the technology advances"--
電子資源:	https://onlinelibrary.wiley.com/doi/book/10.1002/9781119671404

Genome editing in drug discovery[electronic resource] /
Genome editing in drug discovery[electronic resource] /Marcello Maresca, Sumit Deswal. - Hoboken, NJ :Wiley,2022. - 1 online resource (x, 342 p.) :ill. (chiefly col.)

Includes bibliographical references and index.

"CRISPR-Cas has revolutionized genome editing by allowing researchers to remove, alter, or add sections of the DNA sequence. By performing large scale functional genomics screens with CRISPR-Cas, scientists can identify and validate drug targets at a much faster rate. Genome editing is now part of almost every step in the drug discovery pipeline, from target identification and its validation to mechanistic studies in relevant disease models to therapeutic genome editing and disease diagnosis. Genome Editing in Drug Discovery offers comprehensive coverage of the revolution CRISPR-Cas has brought to genome editing and its impact on drug discovery. Ideal for academics, researchers, and professionals in the pharmaceutical industry; this book helps readers create better disease models, assess the safety and efficacy of drugs, discover new targets, and develop next-generation diagnostics for disease-related genes. This book provides a historical prospective on genome editing, discusses the general approaches used to make disease models, and offers practical suggestions as the technology advances"--

ISBN: 9781119671404

Standard No.: 10.1002/9781119671404doiSubjects--Topical Terms:

339189
Drug development.

LC Class. No.: RM301.25 / .G46 2022

Dewey Class. No.: 615.1/9

Genome editing in drug discovery[electronic resource] /
LDR:02247cmm a2200325 a 4500 001 539231
003 OCoLC
005 20220429120813.0
006 m o d
007 cr cnu---unuuu
008 231121s2022 njua ob 001 0 eng
020 $a 9781119671404 $q (electronic bk.)
020 $a 111967140X $q (electronic bk.)
020 $a 9781119671398 $q (epub)
020 $a 1119671396 $q (epub)
020 $a 9781119671381 $q (ePDF)
020 $a 1119671388 $q (ePDF)
020 $z 9781119671343 $q (hbk.)
024 7 $a 10.1002/9781119671404 $2 doi
035 $a 1258041328
040 $a DLC $b eng $c DLC $d OCLCO $d OCLCF $d DG1 $d OCLCO $d UKAHL $d YDX
041 0 $a eng
050 0 4 $a RM301.25 $b .G46 2022
082 0 0 $a 615.1/9 $2 23
245 0 0 $a Genome editing in drug discovery $h [electronic resource] / $c Marcello Maresca, Sumit Deswal.
260 $a Hoboken, NJ : $b Wiley, $c 2022.
300 $a 1 online resource (x, 342 p.) : $b ill. (chiefly col.)
504 $a Includes bibliographical references and index.
520 $a "CRISPR-Cas has revolutionized genome editing by allowing researchers to remove, alter, or add sections of the DNA sequence. By performing large scale functional genomics screens with CRISPR-Cas, scientists can identify and validate drug targets at a much faster rate. Genome editing is now part of almost every step in the drug discovery pipeline, from target identification and its validation to mechanistic studies in relevant disease models to therapeutic genome editing and disease diagnosis. Genome Editing in Drug Discovery offers comprehensive coverage of the revolution CRISPR-Cas has brought to genome editing and its impact on drug discovery. Ideal for academics, researchers, and professionals in the pharmaceutical industry; this book helps readers create better disease models, assess the safety and efficacy of drugs, discover new targets, and develop next-generation diagnostics for disease-related genes. This book provides a historical prospective on genome editing, discusses the general approaches used to make disease models, and offers practical suggestions as the technology advances"-- $c Provided by publisher.
588 $a Description based on print version record.
650 0 $a Drug development. $3 339189
650 0 $a Genetic engineering. $3 223322
700 1 $a Maresca, Marcello. $3 767665
700 1 $a Deswal, Sumit. $3 767666
856 4 0 $u https://onlinelibrary.wiley.com/doi/book/10.1002/9781119671404